Patents by Inventor Kenneth W. Dobie

Kenneth W. Dobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of G protein-coupled receptor 3 expression
    Publication number: 20040110139
    Abstract: Compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor 3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding G protein-coupled receptor 3. Methods of using these compounds for modulation of G protein-coupled receptor 3 expression and for diagnosis and treatment of disease associated with expression of G protein-coupled receptor 3 are provided.
    Type: Application
    Filed: December 10, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Kenneth W. Dobie
  • Modulation of ABCC2 expression
    Publication number: 20040110699
    Abstract: Compounds, compositions and methods are provided for modulating the expression of ABCC2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ABCC2. Methods of using these compounds for modulation of ABCC2 expression and for diagnosis and treatment of disease associated with expression of ABCC2 are provided.
    Type: Application
    Filed: December 10, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Kenneth W. Dobie
  • Modulation of AP-2 alpha expression
    Publication number: 20040109848
    Abstract: Compounds, compositions and methods are provided for modulating the expression of AP-2 alpha. The compositions comprise oligonucleotides, targeted to nucleic acid encoding AP-2 alpha. Methods of using these compounds for modulation of AP-2 alpha expression and for diagnosis and treatment of disease associated with expression of AP-2 alpha are provided.
    Type: Application
    Filed: December 9, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Nicholas M. Dean, Susan M. Freier, Kenneth W. Dobie
  • Modulation of mitochondrial ribosomal protein L13 expression
    Publication number: 20040110158
    Abstract: Compounds, compositions and methods are provided for modulating the expression of mitochondrial ribosomal protein L13. The compositions comprise oligonucleotides, targeted to nucleic acid encoding mitochondrial ribosomal protein L13. Methods of using these compounds for modulation of mitochondrial ribosomal protein L13 expression and for diagnosis and treatment of disease associated with expression of mitochondrial ribosomal protein L13 are provided.
    Type: Application
    Filed: December 10, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Kenneth W. Dobie, Tamara Balac Sipes
  • Modulation of SEDL expression
    Publication number: 20040110160
    Abstract: Compounds, compositions and methods are provided for modulating the expression of SEDL. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SEDL. Methods of using these compounds for modulation of SEDL expression and for diagnosis and treatment of disease associated with expression of SEDL are provided.
    Type: Application
    Filed: December 10, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Kenneth W. Dobie, Tamara Balac Sipes
  • Modulation of BAF53 expression
    Publication number: 20040110147
    Abstract: Compounds, compositions and methods are provided for modulating the expression of BAF53. The compositions comprise oligonucleotides, targeted to nucleic acid encoding BAF53. Methods of using these compounds for modulation of BAF53 expression and for diagnosis and treatment of disease associated with expression of BAF53 are provided.
    Type: Application
    Filed: December 9, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Kenneth W. Dobie, Ravi Jain
  • Modulation of DR1-associated protein 1 expression
    Publication number: 20040110703
    Abstract: Compounds, compositions and methods are provided for modulating the expression of DR1-associated protein 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DR1-associated protein 1. Methods of using these compounds for modulation of DR1-associated protein 1 expression and for diagnosis and treatment of disease associated with expression of DR1-associated protein 1 are provided.
    Type: Application
    Filed: December 10, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Ming-Yi Chiang, Kenneth W. Dobie
  • Modulation of AAC-11 expression
    Publication number: 20040110142
    Abstract: Compounds, compositions and methods are provided for modulating the expression of AAC-11. The compositions comprise oligonucleotides, targeted to nucleic acid encoding AAC-11. Methods of using these compounds for modulation of AAC-11 expression and for diagnosis and treatment of disease associated with expression of AAC-11 are provided.
    Type: Application
    Filed: December 9, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Kenneth W. Dobie
  • Modulation of MALT1 expression
    Publication number: 20040110145
    Abstract: Compounds, compositions and methods are provided for modulating the expression of MALT1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding MALT1. Methods of using these compounds for modulation of MALT1 expression and for diagnosis and treatment of disease associated with expression of MALT1 are provided.
    Type: Application
    Filed: December 9, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Nicholas M. Dean, Kenneth W. Dobie
  • Modulation of zinedin expression
    Publication number: 20040110701
    Abstract: Compounds, compositions and methods are provided for modulating the expression of zinedin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding zinedin. Methods of using these compounds for modulation of zinedin expression and for diagnosis and treatment of disease associated with expression of zinedin are provided.
    Type: Application
    Filed: December 10, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Kenneth W. Dobie, Tamara Balac Sipes
  • Modulation of EMAP-II expression
    Publication number: 20040110144
    Abstract: Compounds, compositions and methods are provided for modulating the expression of EMAP-II. The compositions comprise oligonucleotides, targeted to nucleic acid encoding EMAP-II. Methods of using these compounds for modulation of EMAP-II expression and for diagnosis and treatment of disease associated with expression of EMAP-II are provided.
    Type: Application
    Filed: December 9, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Nicholas M. Dean, Kenneth W. Dobie
  • Modulation of ornithine decarboxylase 1 expression
    Publication number: 20040110148
    Abstract: Compounds, compositions and methods are provided for modulating the expression of ornithine decarboxylase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ornithine decarboxylase 1. Methods of using these compounds for modulation of ornithine decarboxylase 1 expression and for diagnosis and treatment of disease associated with expression of ornithine decarboxylase 1 are provided.
    Type: Application
    Filed: December 10, 2002
    Publication date: June 10, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie
  • Antisense modulation of PTPN12 expression
    Patent number: 6743909
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTPN12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN12. Methods of using these compounds for modulation of PTPN12 expression and for treatment of diseases associated with expression of PTPN12 are provided.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: June 1, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Lex M. Cowsert, Kenneth W. Dobie
  • Modulation of Notch3 expression
    Publication number: 20040102390
    Abstract: Compounds, compositions and methods are provided for modulating the expression of Notch3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Notch3. Methods of using these compounds for modulation of Notch3 expression and for diagnosis and treatment of disease associated with expression of Notch3 are provided.
    Type: Application
    Filed: November 21, 2002
    Publication date: May 27, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Susan M. Freier, Kenneth W. Dobie
  • Modulation of B7H expression
    Publication number: 20040102398
    Abstract: Compounds, compositions and methods are provided for modulating the expression of B7H. The compositions comprise oligonucleotides, targeted to nucleic acid encoding B7H. Methods of using these compounds for modulation of B7H expression and for diagnosis and treatment of disease associated with expression of B7H are provided.
    Type: Application
    Filed: November 23, 2002
    Publication date: May 27, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Kenneth W. Dobie
  • Modulation of jagged 1 expression
    Publication number: 20040102401
    Abstract: Compounds, compositions and methods are provided for modulating the expression of jagged 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding jagged 1. Methods of using these compounds for modulation of jagged 1 expression and for diagnosis and treatment of disease associated with expression of jagged 1 are provided.
    Type: Application
    Filed: November 22, 2002
    Publication date: May 27, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, C. Frank Bennett, Kenneth W. Dobie
  • Modulation of KU86 expression
    Publication number: 20040102404
    Abstract: Compounds, compositions and methods are provided for modulating the expression of Ku86. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Ku86. Methods of using these compounds for modulation of Ku86 expression and for diagnosis and treatment of disease associated with expression of Ku86 are provided.
    Type: Application
    Filed: November 23, 2002
    Publication date: May 27, 2004
    Applicants: Isis Pharmaceuticals Inc., Jewish General Hospital
    Inventors: Brett P. Monia, Kenneth W. Dobie, Lawrence Panasci
  • Modulation of forkhead box C2 expression
    Publication number: 20040102621
    Abstract: Compounds, compositions and methods are provided for modulating the expression of forkhead box C2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding forkhead box C2. Methods of using these compounds for modulation of forkhead box C2 expression and for diagnosis and treatment of disease associated with expression of forkhead box C2 are provided.
    Type: Application
    Filed: November 21, 2002
    Publication date: May 27, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Kenneth W. Dobie
  • Modulation of hepatocyte growth factor receptor expression
    Publication number: 20040102622
    Abstract: Compounds, compositions and methods are provided for modulating the expression of hepatocyte growth factor receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding hepatocyte growth factor receptor. Methods of using these compounds for modulation of hepatocyte growth factor receptor expression and for diagnosis and treatment of disease associated with expression of hepatocyte growth factor receptor are provided.
    Type: Application
    Filed: November 23, 2002
    Publication date: May 27, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, C. Frank Bennett, Kenneth W. Dobie
  • Modulation of Gankyrin expression
    Publication number: 20040102391
    Abstract: Compounds, compositions and methods are provided for modulating the expression of Gankyrin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Gankyrin. Methods of using these compounds for modulation of Gankyrin expression and for diagnosis and treatment of disease associated with expression of Gankyrin are provided.
    Type: Application
    Filed: November 21, 2002
    Publication date: May 27, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Nicholas M. Dean, Kenneth W. Dobie